文献速递血栓与止血

抗CD20联合mTOR抑制及凝血因子VIII用于难治性抑制物血友病A的免疫耐受诱导

Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.
PubMed 文献 · J Thromb Haemost · 2020-03-02

两例传统免疫耐受诱导失败的难治性抑制物血友病A患者接受利妥昔单抗、雷帕霉素联合凝血因子VIII方案,一例完全耐受、一例部分耐受,年化出血率均显著改善。FVIII特异性免疫球蛋白而非总Treg计数与耐受诱导相关。该方案或可考虑用于难治性抑制物患者的FVIII耐受诱导,但机制仍需进一步明确。

要点

  • 抗CD20联合mTOR抑制及FVIII方案在难治性抑制物血友病A中可实现完全或部分FVIII耐受
  • 两例患者年化出血率均显著改善
  • FVIII特异性免疫球蛋白而非总Treg计数与耐受诱导相关,IL-6和IL-21分别与完全耐受诱导相关

核心结论

  • 抗CD20联合mTOR抑制及FVIII方案或可考虑用于难治性抑制物血友病A患者的FVIII耐受诱导,但需进一步表征FVIII特异性免疫反应以阐明免疫耐受机制。

研究设计与样本

  • 两例传统免疫耐受诱导失败的难治性血友病A抑制物患者接受利妥昔单抗、雷帕霉素及FVIII免疫耐受诱导治疗。
  • 随访患者临床病程、抗FVIII免疫球蛋白、细胞因子及选择性淋巴细胞。

主要发现

  • 一例患者达到完全FVIII耐受,另一例达到部分FVIII耐受,两例年化出血率均显著改善。
  • FVIII特异性免疫球蛋白与耐受诱导相关,而总Treg计数与耐受诱导不相关。
  • IL-6和IL-21与完全耐受诱导相关,可能分别支持下调T效应细胞和IgG4产生参与耐受诱导发病机制。

临床怎么用

  • 对于传统免疫耐受诱导失败的难治性抑制物血友病A患者,可考虑抗CD20联合mTOR抑制及FVIII方案进行FVIII耐受诱导。

局限性

  • 仅两例患者,样本量小。
  • 需进一步表征FVIII特异性免疫反应以阐明免疫耐受机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemophilia A (HA) inhibitor patients that fail traditional immune tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 mediated transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction. METHODS: Two refractory HA inhibitor patients were treated with rituximab, rapamycin, and FVIII ITI. Their clinical course, anti-FVIII immunoglobulins, cytokines, and select lymphocytes were followed. RESULTS: One patient achieved complete and the other partial FVIII tolerance; both had marked annualized bleeding rate improvement. FVIII-specific immunoglobulins, but not total Treg counts, correlated with tolerance induction. IL-6 and IL-21 correlation with complete tolerance induction may support that down-regulation of T effectors and IgG4 production, respectively, contribute to the pathogenesis of tolerance induction. CONCLUSIONS: This regimen may be considered to induce FVIII tolerance in HA patients with refractory inhibitors. Further characterization of the FVIII-specific immune response is necessary to clarify the mechanism of immune tolerance.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Doshi BS, Raffini LJ, George LA, et al. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors. J Thromb Haemost. 2020. PMID: 31985872. doi:10.1111/jth.14740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。